Prior Authorizations for Diagnostic Skin Biopsies
Authors:
- 1 November 2017
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (11) , 1091-1092
Abstract
In dermatology, prior authorizations (PAs) have become a common administrative tool that payers use to manage the utilization of biologics and other expensive therapies.1 PAs require physicians to obtain pretreatment approval from a patient’s insurer for the reimbursement of a specific drug or service. PAs are meant to control costs by preventing the inappropriate use of medical resources.Keywords
This publication has 4 references indexed in Scilit:
- Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic reviewBritish Journal of Cancer, 2015
- US Physician Practices Versus Canadians: Spending Nearly Four Times As Much Money Interacting With PayersHealth Affairs, 2011
- Prior authorization for topical psoriasis treatments: Is it cost-beneficial for managed care?Journal of Dermatological Treatment, 2009
- The US dermatology workforce: A specialty remains in shortageJournal of the American Academy of Dermatology, 2008